Abstract
Objectives: Children and young people with CF taking elexacaftor/tezacaftor/ivacaftor (ETI), have shown increases in weight and BMI, however these markers do not distinguish between gain in fat mass (FM) or fat-free mass (FFM). FFM has a stronger association with FEV1 than BMI [ 1 Calella P et al. Nutrition. 2018; 55–56: 131-139 Crossref PubMed Scopus (40) Google Scholar ]. No studies have reported the impact of ETI on body composition (BC) in paediatric populations. We sought to assess anthropometry and BC in 6–11 year olds after starting ETI.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
